Transcriptional regulation is critical for the human immunodeficiency virus 1 (HIV-1) life cycle and is the only step at which the virus amplifies the content of its genetic information. Numerous known and still unknown transcriptional factors, both host and viral, regulate HIV-1 gene expression and latency. This article is a comprehensive review of transcription factors involved in HIV-1 gene expression and presents the significant implications of nuclear factor kappa B (NF-κB) and the HIV-1 transactivator of transcription (Tat) protein. We include recent findings on chromatin remodeling toward HIV transcription and its therapeutic implication is also discussed. The current status of small-molecular-weight compounds that affect HIV transcription is also described.
Get full access to this article
View all access options for this article.
References
1.
Barre-SinoussiF, ChermannJC, ReyFet al.Isolation of retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)Science, 1983; 220:868–871.
2.
GalloRC. Human retroviruses after 20 years: A perspective from the past and prospects for their future. Immunol Rev, 2002; 185:236–265.
3.
PalellaFJJr, DelaneyKM, MoormanACet al.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med, 1998; 338:853.
4.
PomerantzRJ, HornDL. Twenty years of therapy for HIV-1 infection. Nature Med, 2003; 9:867–874.
5.
RichmanDD, MargolisDM, DeLaneyMet al.The challenge of finding a cure for HIV infection. Science, 2009; 323:1304–1307.
6.
HirschMS, Brun-VezinetF, D'AquilaRTet al.Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA, 2000; 283:2417–2426.
7.
SilicianoRF. Scientific rationale for antiretroviral therapy in 2005: Viral reservoirs and resistance evolution. Top HIV Med, 2005; 13:96–100.
8.
RathbunRC, LiedtkeMD, LockhartSM, GreenfieldRA. Antiretroviral therapy for HIV infection. http://emedicine.medscape.com/ article/1533218UpdatedAugust11, 2011.
9.
CoirasM, Huertas-LopezMR, Olmeda-PerezMet al.Understanding the HIV-1 latency provides clues for the eradication of long term reservoirs. Nature Rev Microbiol, 2009; 7:798–812.
10.
ChunTW, CarruthL, FinziDet al.Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 1997; 387:183–188.
11.
GeeraertL, KrausG, PomerantzRJ. Hide-and-seek: The challenge of viral persistence in HIV-1 infection. Annu Rev Med, 2008; 59:487–501.
12.
HoDD, NeumannAU, PerelsonAS, ChenW, LeonardJM, MarkowitzM. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 1995; 373:123–126.
GaynorR. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS, 1992; 6:347–363.
15.
VerdinE. DNAse I-hypersensitivity sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type I. J Virol, 1991; 65:6790–6799.
16.
VerdinE, ParasPJr, Van LintC. Chromatin disruption in the promoter of human immunodeficiency virus type I during transcriptional activation. EMBO J, 1993; 12:3249–3259.
17.
WilliamsSA, ChenF, KwonH, Ruiz-JaraboCM, VerdinE, GreeneWC. NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J, 2006; 25:139–149.
18.
JordanA, BisgroveD, VerdinE. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 2003; 22:1868–1877.
19.
WolschendorfF, DuvergerA, JonesJet al.Hit-and-run stimulation: A novel concept to reactivate latent HIV-1 infection without cytokine induction. J Virol, 2010; 84:8712–8720.
20.
WeinbergerLS, BurnettJC, ToettcherJE, ArkinAP, SchafferDV. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell, 2005; 122:169–182.
21.
LenasiT, ContrerasX, PeterlinBM. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe, 2008; 4:123–133.
22.
WilliamsSA, KwonH, ChenLF, GreeneWC. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol, 2007; 81:6043–6056.
23.
HakreS, ChavezL, ShirakawaK, VerdinE. Epigenetic regulation of HIV latency. Curr Opin HIV AIDS, 2011; 6:19–24.
24.
SigalA, KimJT, BalazsABet al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature, 2011; 477,7362:95–98.
25.
PumferyA, DengL, MaddukuriAet al.Chromatin remodeling and modification during HIV-1 Tat-mediated transcription. Curr HIV Res, 2003; 1:343–362.
26.
RosenCA, SodroskiJG, HaseltineWA. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell, 1985; 41:813–823.
27.
SiekvitzM, JosephsSF, DukovichM, PefferM, Wong-StaalF, GreeneWC. Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-1. Science, 1987; 238:1575–1578.
28.
HooverT, MikovitsJ, CourtD, LiuYL, KungHF, Raziuddin. A nuclear matrix-specific factor that binds a specific segment of the negative regulatory element (NRE) of HIV-1 LTR and inhibits NF-kappa(B) activity. Nucleic Acids Res, 1996; 24:1895–1900.
29.
SreenathK, PavithraL, SinghSet al.Nuclear matrix protein SMAR1 represses HIV-1 LTR mediated transcription through chromatin remodeling. Virology, 2010; 400:76–85.
30.
PereiraLA, BentleyK, PeetersA, ChurchillMJ, DeaconNJ. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res, 2000; 28:663–668.
31.
OkamotoT, Wong-StaalF. Demonstration of virus-specific transcriptional activator(s) in cells infected with HTLV-III by an in vitro cell-free system. Cell, 1986; 47:29–35.
32.
RoyS, DellingU, ChenCH, RosenCA, SonenbergN. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev, 1990; 4:1365–1373.
33.
CoullJJ, RomerioF, SunJMet al.The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol, 2000; 74:6790–6799.
34.
PazinMJ, SheridanPL, CannonKet al.NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev, 1996; 10:37–49.
35.
ImaiK, OkamotoT. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem, 2006; 281:12495–12505.
36.
Van LintC, AmellaCA, EmilianiS, JohnM, JieT, VerdinE. Transcriptional factor binding sites downstream of the human immunodeficiency virus type I transcription start site are important for virus infectivity. J Virol, 1997; 71:6113–6127.
37.
ColinL, Van LintC. Molecular control of HIV-1 postintegration latency: Implications for the development of new therapeutic strategies. Retrovirology, 2009; 6:111(review).
38.
GhoshS, MayMJ, KoppEB. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol, 1998; 16:225–260.
39.
JiangX, TakahashiN, MatsuiNet al.The NF-κB activation in lymphotoxin β receptor signaling depends on the phosphorylation of p65 at serine 536. J Biol Chem, 2003; 278:919–926.
40.
HaydenMS, GoshS. Signaling to NF-kappaB. Genes Dev, 2004; 18:2195–2224.
41.
PomerantzJL, BaltimoreD. Two pathways to NF-κB. Mol Cell, 2002; 10:693–701(preview).
42.
BabaM. Recent status of HIV-1 gene expression inhibitors. Antivir Res, 2006; 71:301–306(mini-review).
43.
VictorianoAF, AsamitsuK, HibiY, ImaiK, BarzagaNG, OkamotoT. Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IkappaB kinase inhibitor. Antimicrob Agents Chemother, 2006; 50:547–555.
44.
AmiciC, BelardoG, RozeraC, BernasconiD, SantoroMG. Inhibition of herpesvirus-induced HIV-1 replication by cyclopentenone prostaglandins: Role of IkappaB kinase (IKK)AIDS, 2004; 18:1271–1280.
45.
AsamitsuK, YamaguchiT, NakataKet al.Inhibition of human immunodeficiency virus type 1 replication by blocking IkappaB kinase with noraristeromycin. J Biochem, 2008; 144:581–589.
46.
KwonH, PelletierN, DeLucaCet al.Inducible expression of IκBα repressor mutants interferes with NF-κB activity and HIV-1 replication in Jurkat T cells. J Biol Chem, 1998; 273:7431–7440.
47.
MoriuchiM, YoshimineH, OishiK, MoriuchiH. Norepinephrine inhibits human immunodeficiency virus type-1 infection through the NF-kappaB inactivation. Virology, 2006; 345:167–173.
48.
SanchoR, de la VegaL, MachoA, AppendinoG, Di MarzoV, MunozE. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. J Immunol, 2005; 175:3990–3999.
49.
SharmaRK, OtsukaM, PandeVet al.Evans Blue is an inhibitor of nuclear factor-kappaB (NF-κB)-DNA binding. Bioorg Med Chem Lett, 2004; 14:6123–6127.
50.
IordanskiyS, IordanskayaT, QuivyV, Van LintC, BurkrinskyM. B-oligomer of pertussis toxin inhibits HIV-1 LTR-driven transcription through suppression of NF-κB p65 subunit activation. Virology, 2002; 302:195–2006.
51.
MarquezN, SanchoR, BedoyaLMet al.Mesuol, a natural occurring 4-phenylcoumarin,inhibits HIV-1 replication by targeting the NF-κB pathway. Antiviral Res, 2005; 66:137–145.
52.
Sanchez-DuffhuesG, CalzadoMA, de VinuesaAGet al.Denbinobin, a naturally occurring 1,4-phenanthrenequinone, inhibits HIV-1 replication through an NF-kappaB-dependent pathway. Biochem Pharmacol, 2008; 76:1240–1250.
53.
OkamotoM, OnoM, BabaM. Potent inhibition of HIV type 1 replication by an anti-inflammatory alkaloid, cepharantine, in chronically infected monocytic cells. AIDS Res Hum Retroviruses, 1998; 14:1239–1245.
54.
MitsuhashiS, KishimotoT, UrakiY, OkamotoT, UbukataM. Low molecular weight lignin suppresses activation of NF-κB and HIV-1 promoter. Bioorg Med Chem, 2008; 16:2645–2650.
55.
RoedererM, StaalFJ, RajuPA, ElaSW, HerzenbergLA, HerzenbergLA. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci USA, 1990; 87:4884–4888.
56.
LeeR, BeauparlantP, ElfordH, PonkaP, HiscottJ. Selective Inhibition of IκBα phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds. Virology, 1997; 234:277–290.
57.
MerinJP, MatsuyamaM, KiraT, BabaM, OkamotoT. Alpha-lipoic acid blocks HIV LTR-dependent expression of hygromycin resistance in THP-1 stable transformants. FEBS Lett, 1996; 394:9–13.
58.
SuzukiYJ, PackerL. Inhibition of NF-κB activation by vitamin E derivatives. Biochem Biophys Res Commun, 1993; 193:277–283.
59.
IsraelN, Gougerot-PocidaloMA, AilletF, VirelizierJL. Redox status of cells influences constitutive or induced NF-kappa B translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J Immunol, 1992; 149:3386–3393.
60.
StevensM, PannecouqueC, De ClerqE, BalzariniJ. Pyridine N-oxide derivatives inhibit viral transactivation by interfering with NF-κB binding. Biochem Pharmacol, 2006; 71:1122–1135.
61.
OkamotoT, OgiwaraH, HayashiT, MitsuiA, KawabeT, YodoiJ. Human thioredoxin/adult T-cell leukemia derived factor activates the enhancer binding protein of human immunodeficiency virus type 1 by thiol redox control mechanism. Int Immunol, 1992; 4:811–819.
62.
YangH-C, XingS, ShanLet al.Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest, 2009; 119:3473–3485.
63.
SatoT, AsamitsuK, YangJPet al.Inhibition of human immunodeficiency virus type 1 replication by bioavailable serine/threonine kinase inhibitor, fasudil hydrochloride. AIDS Res Hum Retroviruses, 1998; 14:293–298.
64.
Lopez-HuertasMR, MateosE, Diaz-GilGet al.Protein kinase C {theta} Is a specific target for inhibition of the HIV Type 1 replication in CD4+ T lymphocytes. J Biol Chem, 2011; 286:27363–27377.
65.
PatzoldS, SchneiderJ, RudolphC, MarmeD, SchachteleC. Novel indolocarbazole protein kinase C inhibitors prevent reactivation of HIV-1 in latently infected cells. Antiviral Res, 1993; 22:273–283.
66.
KarinM. Nuclear factor-kappaB in cancer development and progression. Nature, 2006; 441:431–436.
TakPP, GerlagDM, AupperleKRet al.Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum, 2001; 44:1897–1907.
69.
Ben-NeriahY, KarinM. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol, 2011; 12:715–723.
70.
LawrenceT. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol, 2009; 1:a001651.
71.
SenftlebenU, CaoY, XiaoGet al.Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science, 2001; 293:1495–1499.
72.
BonizziG, BebienM, OteroDCet al.Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers. EMBO J, 2004; 23:4202–4210.
73.
WeihF, CamanoJ. Regulation of secondary lymphoid organ development by the nuclear factor–kappaB signal transduction pathway. Immunol Rev, 2003; 195:91–105.
74.
DejardinE. The alternative NF-kappaB pathway from biochemistry to biology: Pitfalls and promises for future drug development. Biochem Pharmacol, 2006; 72:1161–1179.
ChenD, WangM, ZhouS, ZhouQ. HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim. EMBO J, 2002; 24:6801–6810.
77.
BradyJ, KashanchiF. Tat gets the “green” light on transcription initiation. Retrovirology, 2005; 2:69.
78.
RanaTM, JeangKT. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch Biochem Biophys, 1999; 365:175–185.
79.
BerkhoutB, JeangKT. Trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: A quantitative analysis. J Virol, 1989; 63:5501–5504.
80.
BerkhoutB, SilvermanRH, JeangKT. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell, 1989; 59:273–282.
81.
BieniaszPD, GrdinaTA, BogerdHP, CullenBR. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc Natl Acad Sci USA, 1999; 96:7791–7796.
82.
JakobovitsA, SmitsDH, JakobovitsEB, CaponDJ. A discrete element 3′ of human immunodeficiency virus 1 (HIV-1) and HIV-1 mRNA initiation sites mediates transcriptional activation by an HIV trans activator. Mol Cell Biol, 1988; 8:2555.
83.
KaoSY, CalmanAF, LuciwPA, PeterlinBM. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature, 1987; 330:489–493.
84.
PriceDH. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol, 2000; 20:2629.
85.
ZhuY, Pe'eryT, PengJet al.Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev, 1997; 11:2622–2632.
86.
OkamotoT, BenterT, JosephsSF, SadaieMR, Wong-StaalF. Transcriptional activation from the long-terminal repeat of human immunodeficiency virus in vitro. Virology, 1990; 177:606–614.
87.
TakadaN, SandaT, OkamotoHet al. RelA-associated inhibitor blocks transcription of human immunodeficiency virus Type 1 by Inhibiting NF-κB and Sp1 Actions. J Virol, 2002; 76:8019–8030.
88.
YamaguchiY, TakagiT, WadaTet al.NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell, 1999; 97:41–51.
89.
LaspiaMF, RiceAP, MathewsMB. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell, 1989; 59:283–292.
90.
PingYH, RanaTM. DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcriptional elongation. J Biol Chem, 2001; 276:12951–12958.
91.
BraddockM, ThorburnAM, KingsmanAJ, KingsmanSM. Blocking of tat-independent HIV-1 RNA modification by an inhibitor of RNA polymerase II processivity. Nature, 1991; 350:439–441.
92.
HsuMC, SchuttAD, HollyMet al.Inhibition of HIV replication in acute and chronic infection in vitro by a tat antagonist. Science, 1991; 254:1799–1802.
93.
RichterSN, PaluG. Inhibitors of HIV-1 Tat-mediated transactivation. Curr Med Chem, 2006; 13:1305–1315.
94.
BabaM, OkamotoM, MakinoMet al.Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob Agents Chemother, 1997; 41:1250–1255.
95.
BabaM, OkamotoM, KawamuraMet al.Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol Pharmacol, 1998; 53:1097–1103.
96.
ChenS, ChenR, HeM, PangR, TanZ, YangM. Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors. Bioorg Med Chem, 2009; 17:1948–1956.
97.
LapentaC, SpadaM, SantiniSMet al.Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice. Intl Immunol, 2005; 17:469–475.
98.
LitchovikA, EvdokimovAG, LapidotA. Aminoglycoside-arginine conjugates that bind TAR RNA: Synthesis, characterization, and antiviral activity. Biochemistry, 2000; 39:2838–2852.
99.
ChaoSH, PriceDH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem, 2001; 276:31793–31799.
AliA, GhoshA, NathansRSet al.Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. ChemBioChem, 2009; 10:2072–2080.
102.
ManceboHSY, LeeG, FlygareJet al.P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev, 1997; 11:2633–2644.
103.
FujinagaK, IrwinD, GeyerMet al.Optimized chimeras between kinase-inactive mutant Cdk9 and truncated cyclin T1 proteins efficiently inhibit Tat transactivation and human immunedeficiency virus gene expression. J Virol, 2002; 76:10873–10881.
104.
HerediaA, DavisC, BambaDet al.Indirubin-3′-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS, 2005; 19:2087–2095.
105.
JadlowskyJK, NojimaM, OkamotoT, FujinagaK. Dominant negative mutant cyclin T1 proteins that inhibit HIV transcription by forming a kinase inactive complex with Tat. J Gen Virol, 2008; 89:2783–2787.
106.
WangD, de la FuenteC, DengLet al.Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol, 2001; 75:7266–7279.
107.
BaiJ, SuiJ, ZhuRYet al.Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem, 2003; 278:1433–1442.
108.
PagansS, PedalA, NorthBJet al.SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol, 2005; 3:e41.
109.
StevensM, De ClercqE, BalzariniJ. The regulation of HIV-1 transcription: Molecular targets for chemotherapeutic intervention. Med Res Rev, 2006; 26:595–625.
110.
ZhangH-S, ZhouY, WuM-R, ZhouH-S, XuF. Reseveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD+-dependent SIRT1 activity. Life Sci, 2009; 85:484–489.
111.
MassariS, DaelemansD, BarrecaMLet al.A 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication. J Med Chem, 2010; 53:641–648.
112.
GattoB, TabarriniO, MassariSet al.2-Phenylquinolones as inhibitors of the HIV-1 Tat-TAR interaction. ChemMedChem, 2009; 4:935–938.
113.
Kehn-HallK, GuendelI, CarpioIet al.Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by GSK3-beta inhibitors. Virology, 2011; 415:56–68.
114.
BiswasDK, AhlersCM, DezubeBJ, PardeeAB. Cooperative inhibition of NF-κB and tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat. Proc Natl Acad Sci USA, 1993; 90:11044–11048.
115.
TahirovTH, BabayevaND, VarzavandKet al.Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature, 2010; 465:747–751.
116.
BarboricM, NissenR, KanazawaS, Jabrane-FerratN, PeterlinB. NF-κB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell, 2001; 8:327–337.
117.
ChenL, FischleW, VerdinE, GreeneWC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science, 2001; 293:1653–1657.
118.
CoullJJ, RomerioF, SunJMet al.The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol, 2000; 74:6790–6799.
119.
TyagiM, KarnJ. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J, 2007; 26:4985–4995.
120.
JiangG, EspesethA, HazudaDJ, MargolisDM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol, 2007; 81:10914–10923.
121.
ParadaCA, YoonJ-B, RoederRG. A novel LBP-1-mediated restriction of HIV-1 transcription at the level of elongation in vitro. J Biol Chem, 1995; 270:2274–2283.
122.
EasleyR, Van DuyneR, ColeyWet al.Chromatin dynamics associated with HIV-1 Tat-activated transcription. Biochim Biophys Acta, 2010; 1799:275–285.
123.
HeG, MargolisDM. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol, 2002; 22:2965–2273.
124.
Van LintC, EmilianiS, OttM, VerdinE. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J, 1996; 15:1112–1120.
125.
ColinL, Van LintC. Molecular control of HIV-1 postintegration latency: Implications for the development of new therapeutic strategies. Retrovirology, 2009; 6:111.
ContrerasX, SchwenekerM, ChenC-Set al.Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem, 2009; 284:6782–6789.
128.
MoogC, Kuntz-SimonG, Caussin-SchwemlingC, ObertG. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type I replication independently of glutathione levels. J Gen Virol, 1996; 77:1993–1999.
129.
QuivyV, AdamE, ColleteYet al.Synergistic activation of human immunodeficiency virus type I promoter activity by NF-kappaB and inhibitors of deacetylases: Potential perspectives for the development of therapeutic strategies. J Virol, 2002; 76:11091–11103.
ArchinNM, EspesethA, ParkerD, CheemaM, HazudaD, MargolisDM. Expression of latent HIV induced by the potent HDAC inhibitors suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses, 2009; 25:207–212.
132.
CoullJJ, HeG, MelanderC, RuckerVC, DervanPB, MargolisDM. Targeted derepression of the human immunodeficiency virus type I long terminal repeat by pyrrole-imidazole polyamides. J Virol, 2002; 76:12349–12354.
133.
LusicM, MarcelloA, CeresetoA, GiaccaM. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J, 2003; 22:6550–6561.
134.
ArchinNM, KeedyKS, EspesethA, DangH, HazudaDJ, MargolisDM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS, 2009; 23:1799–1806.
135.
VictorianoAF, ImaiK, TogamiHet al.Novel histone deacetylase inhibitor NCH-51 activates latent HIV gene expression. FEBS Lett, 2011; 585:1103–1111.
136.
LinS, ZhangY, YingH, ZhuHZ. HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells. Curr HIV Res, 2011; 9:202–208.
137.
YingH, ZhangY, LinS, HanY, ZhuHZ. Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines. Int J Mol Med, 2010; 1799:726–739.
MatalonS, PalmerBE, NoldMFet al.The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr, 2010; 54:1–9.
BednarikDP, MoscaJD, RajNB. Methylation as a modulator of expression of human immunodeficiency virus. J Virol, 1987; 6:1253–1257.
143.
GordonRK, GinalskiK, RudnickiWRet al.Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. Eur J Biochem, 2003; 270:3507–3517.
144.
IshidaT, HamanoA, KoiwaT, WatanabeT. 5′ long terminal repeat (LTR) selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology, 2006; 3:69.
145.
KwakYT, GuoJ, PrajapatiSet al.Methylation of SPT5 regulates its interaction with RNA polymerase II and transcriptional elongation properties. Mol Cell, 2003; 11:1055–1066.
146.
TanakaJ, IshidaT, ChoiBIet al.Latent HIV-1 reactivation in transgenic mice requires cell cycle-dependent demethylation of CREB/ATF sites in the LTR. AIDS, 2003; 17:167–175.
147.
WillemsenNM, HitchenEM, BodettiTJet al.Protein methylation is required to maintain optimal HIV-1 infectivity. Retrovirology, 2006; 3:92.
148.
ColinL, Van LintC. Molecular control of HIV-1 postintegration latency: Implications for the development of new therapeutic strategies. Retrovirology, 2009; 6:111.
149.
Du CheneI, BasyukE, LinY-Let al.Suv39H1 and HP-1 γ are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J, 2007; 26:424–435.
150.
GrewalSI, MoazedD. Heterochromatin and epigenetic control of gene expression. Science, 2003; 301:798–802.
151.
PearsonR, KimYL, HokelloJet al.Epigenetic silencing of HIV-1 transcription by formation of restrictive chromatin structures at the viral LTR drives the progressive entry of HIV-1 into latency. J Virol, 2008; 82:12291–12303.
152.
MarbanC, SuzanneS, DequiedtFet al.Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J, 2007; 26:412–423.
153.
ImaiK, TogamiH, OkamotoT. Involvement of histoe H3 Lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem, 2010; 285:16538–16545.
154.
FriedmanJ, ChoWK, ChuCKet al.Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of zeste 2 (EZH2)J Virol, 2011201110.1128/JVI.00836-11.
155.
BoulangerMC, LiangC, RusselRSet al.Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol, 2005; 79:124–131.
156.
XieB, InvernizziCF, RichardS, WainbergMA. Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat interactions with both cyclin T1 and the Tat transactivation region. J Virol, 2007; 81:4226–4234.
157.
Van DuyneR, EasleyR, WuWet al.Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR. Retrovirology, 2008; 5:40.
158.
BednarikDP, DuckettC, KimSUet al.DNA CpG methylation inhibits binding of NF-kappa B proteins to the HIV-1 long terminal repeat cognate DNA motifs. New Biol, 1991; 3:969–976.
159.
ManciniDN, SinghSM, ArcherTK, RodenhiserDI. Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors. Oncogene, 1999; 18:4108–4119.
160.
YedavalliVRK, JeangK-T. Methylation: A regulator of HIV-1 replication?Retrovirology, 2007; 4:9.
161.
WangGP, CiuffiA, LeipzigJ, BerryCC, BushmanFD. HIV integration site selection: Analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res, 2007; 17:1186–1194.
162.
KauderSE, BosqueA, LindqvistA, PlanellesV, VerdinE. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog, 2009; 5:e1000495.
163.
LehrmanG, HogueIB, PalmerSet al.Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet, 2005; 366:549–555.
164.
ArchinNM, KeedyKS, EspesethA, DangH, HazudaDJ, MargolisDM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS, 2009; 23:1799–1806.
165.
ReuseRS, CalaoM, KabeyaKet al.Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One, 2009; 4:e6093.
166.
RullasJ, BermejoM, Garcia-PerezJet al.Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir Ther, 2004; 9:545–554.
167.
AdamE, QuivyV, BexFet al.Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. Mol Cell Biol, 2003; 23:6200–6209.
168.
ChoudharySK, ArchinNM, MargolisDM. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4+ T cells. J Infect Dis, 2008; 197:1162–1170.
169.
KlickoV, ArchinN, KaurR, LehrmanG, MargolisDM. Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol, 2006; 80:4570–4579.
170.
RichonVM, EmilianiS, VerdinEet al.A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA, 1998; 95:3003–3007.
171.
ContrerasX, BarboricM, LenasiT, PeterlinBM. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog, 2007; 3:e146.
172.
ChunTW, EngelD, MizellSBet al.Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med, 1999; 5:651–655.
173.
StellbrinkHJ, van LunzenJ, WestbyMet al.Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)AIDS, 2002; 16:1479–1487.
174.
WangFX, XuY, SullivanJet al.IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest, 2005; 115:128–137.
175.
BrooksDG, HamerDH, ArlenPAet al.Molecular characterization, reactivation, and depletion of latent HIV. Immunity, 2003; 19:413–423.
176.
Martin-SerranoJ, FolgueiraL, Lain de LeraTet al.In vitro selective elimination of HIV-infected cells from peripheral blood in AIDS patients by the immunotoxin DAB389CD4. AIDS, 1998; 12:859–863.
177.
RamachandranRV, KatzensteinDA, WoodR, BattsDH, MeriganTC. Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. J Infect Dis, 1994; 170:1009–1013.
178.
Van PraagRM, PrinsJM, RoosMTet al.OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol, 2001; 21:218–226.
179.
SilicianoJD, LaiJ, CallenderMet al.Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis, 2007; 195:833–836.
180.
SteelA, ClarkS, TeoIet al.No change to HIV-1 latency with valproate therapy. AIDS, 2006; 20:1681–1682.
181.
Sagot-LerolleN, LamineA, ChaixMLet al.Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS, 2008; 22:1125–1129.
182.
ArchinNM, CheemaM, ParkerDet al.Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS ONE, 2010; 5:e9390.
183.
Chavez-BlancoA, Segura-PachecoB, Perez-CardenasEet al.Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Caner, 2005; 4:22.
184.
PerelsonAS. Modelling viral and immune system dynamics. Nat Rev Immunol, 2002; 2:28–36.
185.
MullerE, OkamotoT, ReuterP, UgarkovicD, SchroderHC. Functional characterization of Tat protein from human immunodeficiency virus. Evidence that Tat links viral RNAs to nuclear matrix. J Biol Chem, 1990; 256:3803–3808.
